Salata BM, Hutton DS, Levine DA, Froehlich JB, Barnes GD "Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years with Non- Valvular Atrial Fibrillation - A Multiple-Payer-Perspective Analysis" Am J Cardiol 2016;117(1):54-60. PMCID PMC4780215...
dabigatran 150mg (or age-adjusted, sequential dosing) was cost effective with regard to the incremental cost per QALY gained relative to adjusted-dose warfarin in the prevention of stroke and systemic embolism in AF patients, as the results were below generally accepted cost-effectiveness thresholds...
Objective: To evaluate the cost-utility of dabigatran, a direct acting oral anticoagulant (DOAC) at doses of 110mg & 150mg BD compared to warfarin to prevent stroke in Non-valvular atrial fibrillation (NVAF) in the Indian setting.Background: Anticoagulation reduces the risk of stroke among pat...
Medscape - VTE prevention/treatment dosing for Pradaxa (dabigatran), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
Cost of an Emerging Epidemic: an Economic Analysis of Atrial Fibrillation in the UK. Heart 2004; 90:286-92. 10. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation. Circulation 2004;110:1042-6. 11. Fuster V, Rydn LE, Cannom DS,...
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation Neither dabigatran 110 mg nor dual therapy (aspirin and clopidogrel) was cost-effective. CONCLUSIONS: Dabigatran 150 mg (twice daily) was cost-effective ... SV Shah,BF Gage - 《Circulation》 被引量: 1146发表: 2011年 ...
or reduced doses were analyzed for 110 elderly Japanese subjects (mean age, 76 years) treated with apixaban (2.5 or 5.0mg twice daily), dabigatran etexilate (110 or 150mg twice daily), edoxaban (30 or 60mg once daily), or rivaroxaban (10 or 15mg once daily) at one general hospital. ...
Patients have a quality-adjusted life expectancy of 8.998 quality adjusted life years (QALYs) with warfarin and 9.39 QALYs with dabigatran 150 mg twice daily. From Medicare’s perspective, the incremental cost-effectiveness ratio (ICER) comparing dabigatran with warfarin was $35,311 for patients ...
As an alternative to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation, dabigatran could increase life-expectancy and quality-adjusted life-expectancy with only a modest financial impact in Colombia, according to researchers in that country. A cost-effectiveness ...
dabigatran 150mg (or age-adjusted, sequential dosing) was cost effective with regard to the incremental cost per QALY gained relative to adjusted-dose warfarin in the prevention of stroke and systemic embolism in AF patients, as the results were below generally accepted cost-effectiveness thresholds...